Company: ZLAB
Filing Date: 2025-04-18
Form Type: PRE 14A
Source: 0001628280-25-018384
Chunk: 41

Company: Zai Lab Ltd
Filing Date: 2025-04-18
Form: PRE 14A
Chunk 41
---
ener University School of Law.

Joshua Smiley was appointed in March 2022 as our Chief Operating Officer, effective in August 2022 following the completion of his leave with his prior employer, and he was promoted to President and Chief Operating Officer in April 2023. Mr. Smiley is responsible for our corporate strategy and for overseeing our commercial, manufacturing, business development, finance, human resources, information technology, and corporate affairs functions. Mr. Smiley brings to the Company over 26 years of experience working in the biopharmaceutical industry, including experience leading finance, corporate strategy, business development, venture capital, and global business services operations. Prior to joining the Company, Mr. Smiley worked for Eli Lilly and Company (Lilly) from 1995 to March 2022. While at Lilly, he held various global leadership roles with responsibility over finance, corporate strategy, business development, and capital markets activities, including Senior Vice President and Chief Financial Officer from January 2018 to February 2021. Prior to joining Lilly, he worked in investment banking and consulting. Mr. Smiley earned a B.A. in History from Harvard University.

<div align='center'>-29-</div>

| COMPENSATION COMMITTEE INTERLOCKS 
 AND INSIDER PARTICIPATION         |

None of the members of the Compensation Committee has at any time during 2024 been an officer or employee of the Company. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on the Board of Directors or the Compensation Committee.

<div align='center'>-30-</div>

| COMPENSATION DISCUSSION AND ANALYSIS |

This Compensation Discussion and Analysis (“CD&A”) describes our strategy, philosophy, and practices with respect to our executive compensation program for 2024. It also provides information regarding the compensation decisions made with respect to our named executive officers for 2024 and gives context for the information included in the tables that follow this discussion.

For 2024, our named executive officers were:

| Name               |     | Position                                                                    |
| Samantha (Ying) Du |     | Founder, Chief Executive Officer, and Chairperson of the Board of Directors |
| Yajing Chen        |     | Chief Financial Officer                                                     |
| Rafael G. Amado    |     | President, Head of Global Research and Development                          |
| F. Ty Edmondson    |     |